Upregulation of MIF as a defense mechanism and a biomarker of Alzheimer’s disease

Si Zhang†, Jiehao Zhao‡, Yuhu Zhang‡, Yun Zhang†, Fang Cai†, Lijuan Wang‡* and Weihong Song†*

Abstract

Background: Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine. Chronic inflammation induced by amyloid β proteins (Aβ) is one prominent neuropathological feature in Alzheimer’s disease (AD) brain.

Methods: Elisa, Western blot, and immunohistochemical staining analysis were performed to examine the level of MIF protein in CSF and brain tissues. MTT and LDH assays were used to examine the neurotoxicity, and the Morris Water Maze test was performed to examine the cognitive function in the MIF+/−/APP23 transgenic mice.

Results: MIF expression was upregulated in the brain of AD patients and AD model mice. Elevated MIF concentration was detected in the cerebrospinal fluid of AD patients but not in that of the patients suffering from mild cognitive impairment and vascular dementia. Reduced MIF expression impaired learning and memory in the AD model mice. MIF expression largely associates with Aβ deposits and microglia. The binding assay revealed a direct association between MIF and Aβ oligomers. Neurons instead of glial cells were responsible for the secretion of MIF upon stimulation by Aβ oligomers. In addition, overexpression of MIF significantly protected neuronal cells from Aβ-induced cytotoxicity.

Conclusion: Our study suggests that neuronal secretion of MIF may serve as a defense mechanism to compensate for declined cognitive function in AD, and increased MIF level could be a potential AD biomarker.

Keywords: Alzheimer’s disease, Amyloid, MIF, Microglia, Neuronal toxicity, Cognitive impairment

Introduction

Alzheimer’s disease (AD) is the most common cause of dementia. It is characterized by the intracellular neurofibrillary tangles, extracellular neuritic plaques, and neuronal loss. Extracellular neuritic plaques are the unique feature distinguishing AD from other forms of dementia and neurodegenerative diseases. Amyloid β protein (Aβ), the central component of neuritic plaques, is generated from the amyloid precursor protein by β– and γ–secretase cleavages [1, 2]. One of the common features of AD neuropathology is the activation of microglia and neuroinflammation. Aβ deposits are particularly potent in the activation of microglia [3]. Despite clear evidence of the recruitment of microglia to the vicinity of plaques, there are ongoing debates on the function of the recruited microglia and how microglia participate in Aβ deposition and clearance during AD pathogenesis. In addition, microglia are the primary immune cells responsible for cytokine production, including pro- and anti-inflammatory cytokines as well as growth factors [4], thus potentially serving as a double-edged sword in response to stimuli depending on the physiopathological status of the brain.

Macrophage migration inhibitory factor (MIF) is a pleiotropic protein that participates in many cellular activities and plays an essential role in regulating the inflammatory response, energy metabolism, and apoptosis. MIF has been shown to be beneficial in promoting survival of cardiomyocytes during cardiac ischemia/reperfusion (I/R) by inhibiting apoptosis, reducing ROS production and regulating glucose metabolism [5–7]. Previously, we have shown upregulation of MIF by hypoxia in the acute phase
of stroke [8, 9] and demonstrated the protective role of MIF in suppressing oxidative stress-induced caspase-3 activation [10]. MIF has also been identified as a PARP-1 (Poly (ADP-Ribose) Polymerase 1)-dependent AIF (apoptosis-inducing factor)-associated nuclease (PAAN), and disruption of MIF’s nuclease activity inhibited cell death induced by glutamate excitotoxicity and focal stroke [11]. In AD pathogenesis, neuronal death through apoptotic pathways is observed, and there is evidence suggesting that oxidative stress originating from dysregulation of mitochondria functions serves as a cause of apoptosis [12]. Therefore, MIF may be essential for neuronal survival during AD pathogenesis. In contrast, MIF could also play a deleterious role when overexpressed by immune cells, resulting in excessive inflammation in chronic inflammatory diseases in the systems outside of the CNS [13]. Whether MIF plays a role in initiating and/or maintaining the inflammatory status in the CNS remains unknown. In AD patients, Aβ deposits induce chronic neuroinflammation which features in the activation of resident microglia and infiltration of peripheral macrophages [14]. However, the current understanding of the expression regulation of MIF and its role in AD is limited. This study aimed to investigate how MIF would participate in these seemingly paradoxical roles during AD pathogenesis.

Materials and methods
Cerebrospinal fluid (CSF) and brain tissues
CSF samples were obtained from patients visiting the Guangzhou General Hospital. The control group included patients who had no history or evidence of cognitive decline. CSFs were taken by lumbar puncture under anesthesia when the subjects had surgery for diseases other than inflammatory diseases of the central nervous system. CSFs from patients with AD, mild cognitive impairment (MCI), and vascular dementia (VD) were collected for neurological diagnosis. Table 1 listed the sample information regarding the sample size, sex, and age in each group. Frozen control and AD human cortices were obtained from the Department of Pathology, Columbia University. These samples were used to examine the expression of MIF by immunoblotting experiments. Table 2 listed the sample information regarding the sex, age, and brain areas used in the study.

| Subjects | Sample size (female/male) | Age (mean ± SD) |
|----------|---------------------------|-----------------|
| Control  | 30 (14/16)                | 61.2 ± 9.6      |
| AD       | 28 (14/14)                | 69.4 ± 6.8      |
| MCI      | 10 (4/6)                  | 68.9 ± 9.6      |
| VD       | 17 (8/9)                  | 66.3 ± 10.2     |

| Code | Group | Sex | Age (years) | Area |
|------|-------|-----|-------------|------|
| 1751 | AD    | M   | 76          | Fc   |
| 1780 | AD    | M   | 72          | Fc   |
| 4556 | AD    | F   | 70          | Fc   |
| 4693 | AD    | F   | 70          | Fc   |
| 4854 | AD    | M   | 54          | Fc   |
| 794  | Control | F | 51           | Fc   |
| 1170 | Control | M | 58           | Fc   |
| 1226 | Control | M | 23           | Fc   |
| 1441 | Control | M | 51           | Fc   |
| 4263 | Control | M | 61           | Fc   |

AD Alzheimer’s disease, M male, F female, IB immunoblotting, Fc frontal cortex

Animals
Animal experiment protocols were approved by The University of British Columbia Animal Care and Use Committee. APP23 transgenic mice carry human APP751 cDNA with the Swedish double mutation at positions 670/671 (I670N, M671L) under control of the murine Thy-1.2 expression cassette [15, 16]. The PS45 transgenic mice carry human presenilin-1 cDNA with the G384A mutation [17]. Mif<sup>+/−</sup> mice on the c57/BL6 background were generated by breeding Mif<sup>−/−</sup> mice on BALB/c background (The Jackson Laboratory), with in-house bred c57/BL6 mice. All mice were allowed to access water and food ad libitum. APP23/PS45 double transgenic mice were bred by cross APP23 with PS45 mice. APP23/MIF<sup>+/−</sup> mice were bred by cross APP23 with Mif<sup>−/−</sup> mice on c57/BL6 background. Positive pups were determined by genotyping [18].

The Morris water maze test
The Morris water maze test was performed as previously described [19]. Briefly, the test was performed in a 1.5-m diameter pool with a 10-cm diameter platform placed in the southeastern quadrant of the pool. The procedure consisted of 1 day of visible platform tests and 4 days of hidden platform tests, plus a probe trial 24 h after the last hidden platform test. In the visible platform test, mice were tested for five continuous trials with an inter-trial interval of 60 min. Mouse behavior including distance traveled and escape latency was automatically video-recorded by automated video tracking (ANY-maze, Stoelting). The tests were performed on APP23/MIF<sup>+/−</sup> mice, and APP23 mice, which were negative litter mates of APP23/MIF<sup>−/−</sup> mice. The tests were performed at the ages between 13 and 14 months.

Immunohistology
Half brains were fixed in 4% PFA in PBS. Fixed brains were either dehydrated in 30% sucrose solution followed by cryosectioning at 30 μm thickness or prepared for
paraffin-embedded sectioning at 5 μm thickness. For immunohistochemistry, the brain slices were incubated with 3% hydrogen peroxide in PBS for 10 min, permeabilized in 0.3% Triton X-100 in PBS (PBS-Tx) for 30 min, and blocked with 5% BSA in PBS for 1 h at 22 °C. Next, the slices were incubated with primary antibodies at 4 °C overnight. After rinsing with PBS-Tx for three times, the slices were applied with secondary antibodies for 1 h at 22 °C, followed by 30-min incubation with avidin-biotin-peroxidase complex (ABC, Vector Laboratories). Color development was achieved by the DAB (Vector Laboratories) method. After rinsing with ddH2O, brain sections were subjected to additional hematoxylin staining to visualize nuclei. The sections were observed under traditional microscopy. For Aβ plaque detection, the procedure for secondary antibody incubation was omitted, and the slices were proceeded for ABC incubation and color development. The number of plaques was quantified manually following qualification under ×40 magnification. The area of the plaques was quantified using ImageJ. Images were taken from 10 matching areas (5 slices with 540-μm intervals for each mouse) between APP23 and APP23/MIF +/- transgenic mice. All the images used for plaque quantification were taken at the same time with the same exposure level. For immunofluorescent staining, the brain slices were permeabilized in PBS-Tx for 30 min followed by sequential incubation with primary and fluorescent-labeled secondary antibodies as above. After rinsing with PBS, brain sections were coverslipped using the VECTASHIELD® mounting medium with DAPI (Vector Laboratories) and observed under fluorescent microscopy. The primary antibodies are rabbit anti-MIF antibody (Torrey Pines Biolabs), mouse anti-GFAP antibody, biotinylated 4G8 antibody, rabbit anti-Iba-1 (DAKO). Secondary antibodies are biotinylated swine anti-rabbit IgG (DAKO) for immunohistochemistry, Alexa 488-labeled goat anti-rabbit IgG (Invitrogen), Alexa 594-labeled goat anti-rabbit IgG (Invitrogen), Alexa 488-labeled goat anti-mouse IgG (Invitrogen), and Alexa 594-labeled goat anti-mouse IgG (Invitrogen) for immunofluorescent staining. Primary and secondary antibodies were diluted in PBS with 1% BSA.

**Immunoblotting**

Cortical tissues were homogenized by sonication with 5X (v/v) RIPA-DOC lysis buffer supplemented with a complete mini protease inhibitor cocktail tablet (Roche Molecular Biochemicals). The samples were then centrifuged at 16,000×g at 4 °C for 30 min. The supernatants were removed and added to 2X Novex® tricine SDS sample buffer (Invitrogen) followed by boiling at 100 °C for 2 min. The samples were resolved in 12% tris-tricine gels and transferred to PVDF-FL membranes (Millipore). The membranes were blocked with 5% non-fat milk and incubated with primary antibodies for MIF (Torrey Pines Biolabs) and β-actin (Sigma, AC-15). To detect the proteins, IDye680-labeled goat anti-rabbit and IDye800-labeled goat anti-mouse antibody were used. The blots were scanned using the Odyssey Imager (Licor).

**Cell culture, Aβ oligomer preparation, ELISA, LDH, and MTS assays**

The mouse microglia cell line BV-2, mouse macrophage cell line RAW264.7, human neuroblastoma cell line SHSY-5Y, and a stable cell line overexpressing MIF (SYMS) were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 1 mmol/L of sodium pyruvate, and 2 mmol/L of L-glutamine (Invitrogen). Cells were seeded onto 96-well plates and cultured at 37 °C in an incubator supplemented with 5% CO2. Aβ oligomers were prepared as previously described with modification [20, 21]. Briefly, synthetic Aβ1-42 was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, Fluka), vacuum dried, and dissolved in DMSO as a 5 mM stock. Aβ oligomer was prepared by diluting the stock Aβ in sterile PBS to 100 μM and incubated at 4 °C for 12 h. The oligomers were further diluted to 10 μM or 50 μM by culture medium to treat the cells. LPS was used as a positive control for MIF secretion and was used at the concentration of 100 ng/mL. Sixteen hours after Aβ treatment (10 μM), the culture medium was collected and centrifuged at 3000×g for 2 min at 4 °C prior to assays. MIF concentrations in culture media were measured by a human (R&D systems) or mouse (Mybiosource) MIF ELISA kit following the manufacturer’s instruction. Culture media were diluted five and two times prior to the assays to measure human and mouse MIF concentration, respectively. To assess cell membrane integrity, LDH assay (Promega) following the manufacturer’s instruction was performed using the same batch of culture medium. SHSY-5Y and SYMS were treated with Aβ oligomers (50 μM). To detect Aβ-induced cytotoxicity, MTS assay was performed following the manufacturer’s protocol (Promega).

**Dot blot assay**

To prepare the membrane for the dot blot assay, 2 μL of oligomerized Aβ peptide (100 μM) or purified green fluorescent protein (GFP) protein (approximately 50 μM) were spot on a nitrocellulose membrane and were let dry. The membrane was then blocked in 0.3% BSA in PBS for 1 h at room temperature prior to incubation with mixed proteins of purified hMIF and GFP at the concentration of approximately 5 μM at 4 °C for overnight. The membrane was then washed, and immunoblotting was performed to detect MIF and GFP. The primary antibody to detect MIF was a monoclonal anti-MIF antibody (D-2, Santa-Cruz).
The primary antibody to detect GFP was a polyclonal anti-GFP antibody.

**Results**

**Upregulation of MIF expression in AD**

Postmortem cortical tissues collected from AD patients and controls were assayed by immunoblotting to evaluate the expression of MIF (Fig. 1a). The expression level of MIF was significantly elevated for 1.58 ± 0.14 folds of the controls ($p < 0.05$) (Fig. 1b). To assess the MIF level in AD patients, CSF was collected from control subjects and patients diagnosed with MCI and AD. CSF from patients with VD was also collected. The age and sex distribution of the patients are listed in Table 2. Our results showed that the MIF level in the CSF was significantly upregulated in the patients diagnosed with AD (14.62 ± 1.15 ng/ml) compared to the control subjects (10.07 ± 0.60 ng/ml) ($p < 0.05$) (Fig. 1c). There were no significant differences in the concentration of MIF between the MCI, VD patients (9.89 ± 1.48 and 9.86 ± 0.83 ng/ml, respectively) and the control subjects ($p > 0.05$). However, the MIF level in the MCI and VD patients was significantly lower than that in AD patients ($p < 0.05$) (Fig. 1c). Notably, the CSF concentration of MIF elevated approximately 1.4 folds in AD patients compared to that in control subjects, which was similar as the fold increase in the brain tissue, indicating the level of MIF in CSF could be an indicator of the level of MIF in the brain tissue. Our results demonstrated that MIF was upregulated in AD, and the elevation of MIF in CSF could be a biomarker of AD.

To determine the change of the MIF expression during AD pathology, we measured the expression of MIF in the brain tissue from APP23/PS45 double transgenic mice at different ages. APP23/PS45 mice have an accelerated AD-like pathological progression [17, 22, 23], and by the age of 3 months, the mice have developed a significant amount of plaques and cognitive impairments in behavioral tests. Brain slices obtained from APP23/PS45 mice were stained with thioflavin S and 4G8 for plaque detection. In 2-month old mice, a few plaques appeared in the cortical and hippocampal regions and were scattered in the cortical layers (Fig. 1d). As expected, the number of plaques significantly increased at 3 months of age in all brain regions as indicated by both thioflavin S and 4G8 staining (Fig. 1d). MIF expression levels in cerebral parenchyma were also measured using the same group of mice. Immunoblotting results showed that MIF protein level in the brain tissue was similar between
wildtype and APP23/PS45 mice at the age of 2 months (1.00 ± 0.03 vs 1.02 ± 0.02 folds, \(p > 0.05\)) (Fig. 1e). However, at 3 months of age, MIF expression in the APP23/PS45 mice increased to 1.37 ± 0.05 fold (\(p < 0.05\)) of the WT mice at the same age (Fig. 1e). Our results demonstrated that upregulation of MIF in the APP23/PS45 mice occurred at the late stage of the disease when a large amount of amyloid plaques had been formed.

Increased MIF secretion protects neuronal cells from Aβ-induced neurotoxicity

MIF is a secretory protein and exerts functions via autocrine/paracrine mechanisms. To examine whether Aβ could trigger MIF secretion, we first tested whether MIF could be secreted after Aβ treatment on mouse microglia and mouse macrophage cell lines, BV-2 and RAW 264.7, respectively. LPS was used as a positive control as it triggers MIF secretion in RAW 264.7 [24, 25]. Baseline expression of MIF was detected in the medium from RAW 264.7 at the concentration of 11.73 ± 1.54 pg/mL (Fig. 2a), while not detectable in that from BV-2 (Fig. 2b). After the LPS treatment, the concentration of MIF significantly increased in the culture medium of both cell lines to 18.83 ± 0.88 ng/mL (\(p < 0.05\)) (Fig. 2a) for RAW 264.7 and 14.35 ± 0.86 ng/mL for BV-2 (\(p < 0.05\)) (Fig. 2b). However, Aβ treatment did not significantly alter the concentration of MIF in the medium from RAW 264.7 (9.43 ± 1.24 pg/mL) compared to controls, but it was significantly lower than that from LPS treatment (\(p < 0.01\)) (Fig. 2a). To our surprise, Aβ treatment did not elevate the concentration of MIF above the detection limit in the culture medium from BV-2 (Fig. 2b). LDH assays were performed to examine the cell membrane integrity that could affect the release of MIF. Our result demonstrated that Aβ treatment did not result in cell membrane leakage in both cell lines.

To examine neuronal secretion of MIF by Aβ, we treated SH-SY5Y cells. The baseline release of MIF to the culture medium from the SH-SY5Y was also observed at the concentration of 26.98 ± 0.91 ng/mL (Fig. 2c). In contrast to the increased MIF secretion in RAW264.7 and BV-2, LPS treatment slightly reduced MIF release in SH-SY5Y to the

![Fig. 2](image-url) Increased MIF secretion protects neuronal cells from Aβ-induced neurotoxicity. Cells were seeded on seeded onto 96-well plates and cultured 24 h prior to treatment. Aβ treatment was achieved by adding medium diluted Aβ1-42 oligomer stock solution (100 μM in sterile PBS) at the final concentration of 10 μM or 50 μM. LPS at the concentration of 100 ng/mL was used as a positive control for MIF secretion. Sixteen hours after treatment, the culture medium was collected and centrifuged prior to analysis. Media collected from RAW 264.7 (a), BV-2 (b), and SH-SY5Y (c) cell lines were measured for MIF concentrations by ELISA. Values represent mean ± SEM, \(n = 4\). *\(p < 0.05\) relative to controls by one-way ANOVA with Newman-Keuls post hoc tests. #\(p < 0.05\) relative to LPS by one-way ANOVA with Newman-Keuls post hoc tests. d The same batch of media from SHSY-5Y cells were subjected to LDH assay to evaluate the cell membrane integrity. Values represent mean ± SEM, \(n = 4\). *\(p < 0.05\) relative to controls by one-way ANOVA with Newman-Keuls post hoc tests. e SH-SY5Y and SYMS cell lines were subjected to Aβ oligomer treatment at the final concentration of 50 μM. After 24-h treatment, cell viability was assessed by MTS assays. Values represent mean ± SEM, \(n = 3\). *\(p < 0.05\) relative to controls by two-way ANOVA with Bonferroni’s multiple comparison test.
concentration of 24.36 ± 1.12 ng/mL, compared to controls (p < 0.05) (Fig. 2c). The Aβ treatment on SH-SY5Y cells induced a significant increase of MIF concentrations in the culture medium to 32.97 ± 0.79 ng/mL (Fig. 2c), and the increase was not due to the cell membrane leakage as shown by LDH assay (Fig. 2d). Taken together, our result suggested that Aβ-triggered MIF secretion by neurons.

Next, we examined whether elevated MIF secretion could protect neuronal cells from Aβ-induced toxicity. We generated an SH-SY5Y cell line stably overexpressing MIF (SYMS). We treated the SH-SY5Y and SYMS cells with Aβ oligomers (50 μM). After 24 h, the MTS assay was performed to detect cell viability. We found that Aβ treatment reduced the cell survival rate to 73.64% ± 2.49% in SH-SY5Y cells. However, there was no significant difference in cell viability between Aβ-treated SYMS cells and untreated ones, suggesting that elevated MIF secretion protects neurons from Aβ-induced cytotoxicity (Fig. 2e).

**MIF deficiency impairs cognitive functions**

The above results suggested that neurons were responsible for the MIF secretion triggered by the Aβ deposits. To test whether MIF participates in cognitive performance during AD pathogenesis, APP23/MIF+/− and APP23 mice were subjected to memory function assessment by the Morris water maze at the age between 12 and 13 months. In the visible platform tests, APP23/MIF+/− and APP23 mice had similar escape latencies (40.5 ± 3.0 s and 42.8 ± 4.6 s, p > 0.05) (Fig. 3a) and path length (7.7 ± 0.7 m and 8.7 ± 0.7 m, p > 0.05) (Fig. 3b), indicating that hemizygous knock-out of MIF did not affect mouse mobility or vision. In the hidden platform test, APP23/MIF+/− mice showed significant memory impairment on the fifth day of the test. The escape latency on the last day of the hidden platform test was significantly longer in APP23 mice (28.1 ± 2.9 s vs 15.7 ± 1.4 s, p < 0.05) (Fig. 3c). The APP23/MIF+/− mice also swam significantly longer distances to reach the platform as compared to APP23 mice (4.3 ± 0.5 vs 2.6 ± 0.1 m, p < 0.05) on the fifth day of hidden platform test (Fig. 3d). In the probe trial on the last day of testing, the platform was removed. APP23/MIF+/− mice showed a significantly lower number of times passing through the position of the hidden platform than APP23 mice (P < 0.05) (2.2 ± 0.6 vs 0.8 ± 0.3, p < 0.05) (Fig. 3e). These results indicated that MIF deficiency affected spatial learning during the hidden platform training.

**MIF expression is associated with amyloid plaques**

Since our results suggested that sufficient MIF is necessary for normal cognitive performance, it seems controversial that AD patients with increased MIF levels still demonstrated memory loss. In order to address this discrepancy, we thoroughly analyzed the expression patterns of MIF in the brain. Immunohistology was performed on brain sections from APP23/PS45 mice using a specific anti-MIF antibody. The pattern of MIF staining demonstrated as spotted clusters in both the hippocampal region and cerebral cortex (Fig. 4A), which remarkably resembled that of 4G8 stained Aβ plaques. Next, we performed the double staining of MIF and 4G8 on an adjacent brain section (5 μm) to the one used for the DAB staining. The fluorescent signals for MIF as pointed by white arrows (Fig. 4B) were confirmed by the DAB staining of MIF as pointed by black arrows (Fig. 4A). The double staining of MIF and 4G8 revealed the colocalization of MIF and Aβ plaques (Fig. 4B). Interestingly, two patterns of association between MIF and Aβ plaques were observed. Besides the colocalization as shown in Fig. 4B, b, some MIF staining exhibited a pattern that embraced the dense core of the Aβ plaques in hippocampal (Fig. 4B, a, insert) as well as in cortical (Fig. 4C) regions. There were a few cells stained positive for MIF (arrowheads, Fig. 4B inserts), and we did further analysis to identify the cell type.

Since MIF expression was tightly associated with amyloid plaques, we examined whether glial cells were responsible for the plaque-associated MIF expression. Double staining of MIF and GFAP was performed on brain sections from APP23/PS45 mice at the age of 7 months (Fig. 5a). A similar MIF expression pattern was observed, confirming the characteristics of MIF expression in the AD brains—enriched in the vicinity of amyloid plaques. Active astrocytes stained with GFAP were prevalent in the entire brain section without particular enrichment. At the site of MIF enrichment, MIF expression overlapped with GFAP staining, although the highest expression of GFAP was neither in close vicinity of nor colocalized with MIF (arrows, Fig. 5a). Due to a lack of available antibodies, double staining for colocalization study was not performed for MIF and microglia. Instead, amyloid plaques were stained with 4G8 to locate possible expression of MIF, and Iba-1 was used to detect microglia (Fig. 5b). Our result demonstrated that Iba-1 positive microglia were in closer vicinity to the amyloid plaques than astrocytes, suggesting highly possible overlapping of microglia and MIF expression. In addition, the morphology of MIF expression cells (arrowheads, Fig. 5a) was very similar to Iba-1 stained microglia (arrowheads, Fig. 5b).

**MIF interacts with Aβ oligomers**

Our results strongly suggested a possible association of MIF with amyloid plaques in the extracellular space. However, one could not rule out the possibility that the presence of MIF was merely due to constant secretion by the vicinity cells. In order to examine whether MIF is associated with plaques in the extracellular matrix, we first examined whether MIF could interact with Aβ using a dot blot assay. Oligomerized Aβ and GFP were spot on a
membrane and incubated with the protein mixture of MIF and GFP. GFP spotted on the membrane served as the control for non-specific binding by MIF, and GFP in the protein mixture served as the control for non-specific binding by Aβ. The result demonstrated that MIF interacted with oligomerized Aβ, but neither did MIF nor Aβ interact with GFP, indicating a specific binding between oligomerized Aβ and MIF (Fig. 6a). We then studied whether MIF and Aβ were associated in the AD brain by exploring whether MIF and Aβ present at the same density fraction. Brain tissues were obtained from APP23/PS45 mice and homogenized in PBS with 0.5% Triton X-100. The homogenates were fractionated under 16,000×g for 15 min at 4 °C. The homogenates were clearly separated into four layers, namely supernatant (S), pellet layer 1 (P1), pellet layer 2 (P2), and pellet layer 3 (P3). The supernatants were collected and subjected to ultracentrifugation at 100,000×g for 1 h at 4 °C, and the second supernatants were collected and labeled as S′. The layer P3 mainly consisted of non-uniform tissue debris was discarded. Subsequently, samples collected from S′, P1, and P2 fractions were subjected to immunoblots to locate the presence of Aβ enriched fractions. To study the potential association between plaques and MIF, immunoblots were performed to detect the presence of Aβ and the level of MIF in each collected fraction. Our results demonstrated that Aβ was not detectable in the S′ fraction, but was detected in P1, P2, and P3 fractions (Fig. 6b). Concentrations of MIF were similar between controls and the APP23/PS45 mice in the supernatant, indicating AD pathology did not increase the level of free MIF in

**Fig. 3** MIF deficiency affects cognitive functions in the AD model mice. APP23/MIF+/− and APP23 mice (APP/MIF+− and APP, respectively) at the age of 12 to 13 months were subjected to the Morris water maze test. a During the first day of visible platform tests, the APP23/MIF+/− and APP23 mice exhibited a similar latency to escape onto the visible platform. P > 0.05 by Student’s t test. b APP23/MIF+/− and APP23 mice had similar swimming distances before escaping onto the visible platform. P > 0.05 by Student’s t test. c In hidden platform tests, APP23/MIF+/− mice showed a longer latency to escape on to the hidden platform on the 5th day. *P < 0.05 by two-way ANOVA with Bonferroni post hoc tests. d APP23/MIF+/− mice had a shorter swimming length before escaping onto the hidden platform on the 5th day. *P < 0.05 by two-way ANOVA with Bonferroni post hoc tests. e On the last day of the trial, APP23/MIF+/− showed a significantly lower number of passing times through the location of the platform than APP23 mice. P < 0.05 by Student’s t test.
the soluble fraction (0.96 ± 0.14 fold of the control, \( P > 0.05 \)) (Fig. 6b, c). Interestingly, soluble MIF tended to be enriched in the P1 fraction (1.60 ± 0.31 fold of the control, \( P > 0.05 \)) and was significantly enriched in the P2 fraction (1.92 ± 0.21 fold of the control, \( P < 0.05 \)), where \( \alpha \beta \) aggregates presented (Fig. 6b, c). Taken together, these results are supportive that MIF could bind with \( \alpha \beta \) plaques in AD brains.

**Discussion**

Overproduction of \( \alpha \beta \) leads to chronic inflammation that is characterized by activation of microglia cells and increased production of inflammatory mediators in the brain, such as pro-inflammatory cytokines, chemokines, macrophage inflammatory proteins, and prostaglandins [14]. MIF as a pro-inflammatory cytokine has been shown to be upregulated systemically in circulation and locally at lesion sites in many chronic inflammatory diseases and plays central roles in disease progression. Previous studies have shown that MIF was upregulated in plasma and CSF from AD patients [26–29]. In the present study, we demonstrated that MIF level was increased in the postmortem cortical tissues and CSF of AD patients and the late stage of the AD transgenic mouse brains with a substantial amount of \( \alpha \beta \) deposits. Notably, the MIF level was not altered in either CSF from patients with MCI or brain tissues from young AD transgenic mouse brains, suggesting that MIF probably was not immediately upregulated at the early stage of AD pathology. This result is in line with a previous study showing that among a series of pro-inflammatory cytokines including MIF, only the production of IL-1\( \beta \) was induced in 14-month old APP23 single transgenic mice, which developed a few \( \alpha \beta \) deposits [30]. Interestingly, MIF level was not elevated in patients with VD, indicating the elevation of MIF in the CSF possibly is specific to patients with dementia due to AD. This was indicative that MIF release could be a defense mechanism by neurons, and that was how AD is distinguished from other types of dementia, such as VD.
In addition to temporal expression pattern, our study further characterized the spatial expression pattern of MIF. In our study, we clearly demonstrated that MIF expression immediately surrounds $\text{A}\beta$ plaques. Furthermore, we showed that MIF directly binds with $\text{A}\beta$. Protein associated with $\text{A}\beta$ may affect fibril formation and deposition. For example, cystatin C has been reported to associate with $\text{A}\beta_{42}$ to inhibit the formation of amyloid fibrils [31]. Cystatin C and MIF share a similar tertiary structure with 4-strand $\beta$-sheet, and both undergo self-aggregation morphologically or to filaments at a physiological condition and are amyloidogenic at lower pH in vitro [32, 33]. Because MIF binds to $\text{A}\beta$ directly and colocalizes with $\text{A}\beta$ plaques, whether MIF could affect the amyloidogenesis of $\text{A}\beta$ warrants further studies.

It has been suggested that MIF facilitates defending mechanisms under stressful conditions by promoting cell survival in the systems outside the CNS. During heart ischemia, MIF acts in an autocrine fashion and signals through the CD74/44 receptor complex to promote cell survival by temporarily maintaining energy homeostasis; knockout of MIF thus results in the larger ischemic damage [7]. In the CNS, as we demonstrated, maintaining MIF expression is important in defending cerebral ischemia by reducing oxidative stress-induced caspase-3 activation in neurons during the acute phase [10]. Maintaining MIF expression could also be important for neurons to defend $\text{A}\beta$-induced toxicity. However, there is limited research carried out to investigate the effect of MIF in $\text{A}\beta$-induced toxicity in neurons, except for one study demonstrating a protective effect of a MIF inhibitor on $\text{A}\beta$-induced toxicity in SH-SY5Y cells [26]. In contrast to their results, we identified that $\text{A}\beta$ stimulated the secretion of MIF from SH-SY5Y cells and increased secretion of MIF significantly reduced neuronal cell death induced by $\text{A}\beta$. It has been shown that inhibition of p53 attenuates $\text{A}\beta$-induced toxicity.
neuronal apoptosis [34], and MIF can directly inhibit p53 activation [35]. Thus, secretion of MIF precedes cell damage, and MIF is released under the autocrine fashion, in turn, activates cell survival signals.

It should be noted that MIF acts in an autocrine fashion and interacts with its cell surface receptors to transduce its signals [36, 37]; therefore, secretion of MIF to the extracellular space is necessary for MIF to exert its cellular functions. It has been suggested that MIF is constitutively expressed and is perhaps secreted constantly by neurons in the brain [38, 39]. However, at the late stage of AD, a large portion of the extracellular MIF is sequestered by Aβ plaques, as we demonstrated, and perhaps has no functions anymore, which suggests that increased MIF secretion is essential for maintaining cognitive function during AD development. This also explains why MIF upregulation is observed at the late stage of AD with significantly increased Aβ deposition.

We found that neurons specifically secreted MIF following Aβ stimulation. However, we did not rule out the possibility that upregulation of MIF is also contributed by microglia (local or infiltrated) at the late stage of AD, at which pro-inflammatory cytokines are predominantly produced [14], and they are known to trigger secretion of MIF [25]. Indeed, recent studies demonstrated a mixture of hyperactivated microglia at the late stage of AD pathology [40] and the upregulation of MIF in hyperactivated microglia [41]. We speculated that at the late stage of AD pathology, overproduced MIF could still be beneficial in promoting neuronal survival if it can be received by neurons; on the other hand, however, the pool of MIF produced by immune cells may locally promote their own survival and proliferation, which in turn produce and release more MIF, leading to a vicious circle as seen in chronic inflammatory diseases in the peripheral.

Although it is debatable whether Aβ deposits serve as a cause of cognitive decline during AD, inhibition of Aβ production and plaque formation have been shown to successfully mitigate cognitive deficits in AD model mice [17, 18, 42, 43]. Since MIF insufficiency had an impact on cognitive performance during AD. In contrast, inhibition of MIF has been suggested for treating peripheral inflammatory diseases [13, 26], indicating the possibility that the potential pro-survival and pro-inflammatory functions of MIF counteract each other during AD, and inhibition of one would tip a balance to the other. It is possible that at the early stage with little Aβ plaques formation, MIF secretion triggered by Aβ oligomer is pro-survival for neurons to maintain cognitive function; while at the late stage with abundant Aβ plaques, the compensatory function may fail to demonstrate effects due to the direct binding between MIF and Aβ, leaving behind the pro-inflammatory effects. Therefore, it will be of importance to dissect the
MIF signal complex so that the deleterious effects could be inhibited without affecting the beneficial ones.

Conclusions
In summary, we found that the upregulation of MIF expression specifically occurs in patients with AD rather than other types of dementia and identified that the level of MIF in CSF could serve as a biomarker of AD with global inflammation. In addition, hemizygous knockout of MIF exacerbated memory task performance of APP23 AD model mice. More importantly, we for the first time revealed the direct interaction between MIF and Aβ. Taken together, our data provided first-hand evidence of MIF expression profile during AD and its effect on AD development. Our study suggested that proper regulation of MIF expression, secretion, and function is essential for the successful treatment of AD.

Abbreviations
AD: Alzheimer’s disease; APP: Amyloid β precursor proteins; Aβ: Amyloid β protein; MIF: Macrophage migration inhibitory factor

Authors’ contributions
LW and WS conceived and designed the experiments. SZ, JZ, YuhuZ, and YunZ performed the experiments. SZ, JZ, YuhuZ, YunZ, FC, LW, and WS analyzed and contributed reagents/materials/analysis tools. SZ, YunZ, and WS wrote the paper. All authors reviewed the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by Canadian Institutes of Health Research (CIHR) Operating Grant MOP-142487 to WS. WS was the holder of the Tier 1 Canada Research Chair in Alzheimer’s disease; S.Z. is supported by UBC 4YF Scholarship. YunZ is the recipient of Michael Smith Foundation for Health Research Post-Doctoral Fellowship Award.

Availability of data and materials
The authors agree the availability upon request.

Ethics approval and consent to participate
The study was approved by the Institutional Ethics Committee of the Guangdong General Hospital. Animal experiments were approved by and conducted in accordance with the University of British Columbia Animal Care and Use Committee (Vancouver, BC, Canada) and the Canadian Institutes of Health Research (CIHR) guidelines.

Consent for publication
N/A

Competing interests
The authors declare that they have no competing interests.

Received: 21 January 2019 Accepted: 21 May 2019
Published online: 07 June 2019

References
1. Zhang S, Wang Z, Cai F, Zhang M, Wu Y, Zhang J, Song W. BACE1 cleavage site selection critical for amyloidogenesis and Alzheimer’s pathogenesis. J Neurosci. 2017;37(29):6915–23.
2. Zhang Y, Song W. Islet amyloid polypeptide: another key molecule in Alzheimer’s pathogenesis? Prog Neuropsych. 2017;153:100–20.
3. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease—a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012;2(11a):006346.
4. Colton CA. Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol. 2009;4(4):399–418.
5. Koga K, Kenessev A, Powell SR, Sison CP, Miller EJ, Ojamaa K. Macrophage migration inhibitory factor provides cardioprotection during ischemia/reperfusion by reducing oxidative stress. Antioxid Redox Signal. 2011;14(7):1191–202.
6. Luetscher P, Hendgen-Cotta UB, Sobierajski I, Totozek M, Reeh M, Dewor M, Lue H, Krisp C, Wolters D, Kelim M, et al. Cardioprotection through S-nitrosylation of macrophage migration inhibitory factor. Circulation. 2012;125(15):1880–9.
7. Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, Young LH. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischemic heart. Nature. 2008;451(7178):578–82.
8. Wang L, Zis O, Ma G, Shan Z, Zhang X, Wang S, Dai C, Zhao J, Lin Q, Lin S, et al. Upregulation of macrophage migration inhibitory factor gene expression in stroke. Stroke. 2009;40(3):973–6.
9. Zis O, Zhang S, Sorovin-Z, K, Wang L, Song W. Hypoxia signaling regulates macrophage migration inhibitory factor (MIF) expression in stroke. Mol Neurobiol. 2015;51(1):155–67.
10. Zhang S, Zis O, Ly PT, Wu Y, Zhang M, Cai F, Bucala R, Shyu WC, Song W. Down-regulation of MIF by NRKp29 under hypoxia accelerated neuronal loss during stroke. FASEB J. 2014;28(10):4394–407.
11. Wang Y, An R, Umanah GK, Park H, Nambari K, Eacker SM, Kim B, Bao L, Harraz MW, Chang C, et al. A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Science. 2016;354(6308):aad6872.
12. Eckert A, Keil U, Marques CA, Bonert A, Frey C, Schüssel K, Müller WE. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer’s disease. Biochem Pharmacol. 2003;66(8):1627–34.
13. Morand EF, Leech M, Bernhagen J. MIF, a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov. 2006;5(5):399–410.
14. Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer’s disease, role of cytokines. ScientificWorldJournal. 2012;2012:763537.
15. Sun X, He G, Qing H, Zhou W, Mobie F, Cai F, Staufenbiel M, Huang LE, Song W. Hypoxia facilitates Alzheimer’s disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A. 2006;103(49):18727–32.
16. Sturchler-Pierat C, Abramowski D, Duke M, Wiederhold KH, Miltz C, Rothacher S, Lederbana B, Burki K, Frey P, Paganetti PA, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997;94(24):13287–92.
17. Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, Zhang Z, Wei S, Sun X, Chen CH, et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer’s disease mouse models. J Exp Med. 2008;200(12):2781–9.
18. Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinosita A, Zhang M, Yang Y, Cai F, Woodgett J, et al. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest. 2013;123(1):224–35.
19. Zeng J, Chen L, Wang Z, Chen Q, Fan Z, Jiang H, Wu Y, Ren L, Chen J, Li T, et al. Marginal vitamin A deficiency facilitates Alzheimer’s pathogenesis. Acta Neuropathol. 2017;133(6):967–82.
20. Stine WB Jr, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillation. J Biol Chem. 2003;278(13):11612–22.
21. Fa M, Orozco IJ, Francis YI, Saeed F, Gong Y, Arancio O. Preparation of oligomeric beta-amyloid 1-42 and induction of synaptic plasticity impairment on hippocampal slices. J Vis Exp. 2010;41:1884.
22. Dong Z, Han H, Li H, Bai Y, Wang W, Tu M, Peng Y, Zhou L, He W, Wu X, et al. Long-term potentiation decay and memory loss are mediated by AMPAR endocytosis. J Clin Invest. 2015;125(1):234–47.
23. Huang D, Yu M, Yang S, Lou D, Zhou W, Zheng L, Wang Z, Cai F, Zhou W, Li T et al. Ethanol Alters APP Processing and Aggravates Alzheimer-Associated Phenotypes. Mol Neurobiol. 2018;55(6):5006–18.
24. Flieger O, Engling A, Bucala R, Lue H, Nickel W, Bernhagen J. Regulated secretion of macrophage migration inhibitory factor is mediated by a classical pathway involving an ABC transporter. FEBS Lett. 2003(551)(3):78–86.
25. Gandal T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med. 1994;179(6):1895–902.
26. Bacher M, Deuster O, Aljabari B, Egensperger R, Neff F, Jessen F, et al. The role of macrophage migration inhibitory factor in Alzheimer’s disease. Mol Med. 2010;16(3):386–97.
27. Craig-Chapairo R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perin RR, Bales KR, Soares H, Fagan AM, et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer’s disease diagnosis and prognosis. PLoS One. 2011;6(4):e18850.
28. Popp J, Bacher M, Kolsch H, Noelker C, Deuster O, Dodel R, Jessen F. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J Psychiatr Res. 2009;43(8):749–53.

29. Lee KS, Chung JH, Lee KH, Shin MJ, Oh BH, Hong CH. Bioplex analysis of plasma cytokines in Alzheimer's disease and mild cognitive impairment. Immunol Lett. 2008;121(2):105–9.

30. Mehlhorn G, Hollborn M, Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci. 2000;18(4–5):423–31.

31. Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, Schmidt SD, Nixen RA, Frangiote B, Levy E. Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging. 2004;25(8):1033–43.

32. Levy E, Jaskolski M, Grubb A. The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol. 2006;16(1):60–70.

33. Lashuel HA, Aljabari B, Sigurdsson EM, Metz CN, Leng L, Callaway DJ, Bucala R. Amyloid fibril formation by macrophage migration inhibitory factor. Biochem Biophys Res Commun. 2005;338(2):973–80.

34. Culmsee C, Zhu X, Yu QS, Chan SL, Camandola S, Guo Z, Greig NH, Mattson MP. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem. 2001;77(1):220–8.

35. Hudson JD, Shoalbi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999;190(10):1375–82.

36. Bernhagen J, Krohn R, Hsu H, Gregory JL, Zernecke A, Koenen RR, Zernecke A, Schober A, Leng L, et al. MIF is a noncognate ligand of CXCR chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13(5):587–96.

37. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delcneh T, Chen Y, Mitchell RA, Bucala R. MIF signal transduction initiated by binding to CD74. J Exp Med. 2003;197(11):1467–76.

38. Bacher M, Meinhardt A, Lan HY, Dhabhar FS, Mu W, Metz CN, Chesney JA, Gersma D, Donnelly T, Atkins RA, et al. MIF expression in the rat brain: implications for neuronal function. Mol Med. 1998(4):217–30.

39. Ogata A, Nishihira J, Suzuki T, Nagashima K, Tashiro K. Identification of macrophage migration inhibitory factor mRNA expression in neural cells of the rat brain by in situ hybridization. Neurosci Lett. 1998;246(3):173–7.

40. Yin Z, Raj D, Saipour N, Van Dam D, Brouwer N, Holtman IR, Eggen BJL, Moller T, Tamn JA, Abdourahman A, et al. Immune hyperreactivity of Abeta plaque-associated microglia in Alzheimer's disease. Neurobiol Aging. 2017;55:115–22.

41. Kamphuis W, Kooijman L, Schetters S, Orre M, Hol EM. Transcriptional profiling of CD11c-positive microglia accumulating around amyloid plaques in a mouse model for Alzheimer's disease. Biochim Biophys Acta. 2016;1862(10):1847–60.

42. Richard KL, Filali M, Prêfontaine P, Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1–42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J Neurosci. 2008;28(22):5784–93.

43. Sevigny J, Chioa I, Bussiere T, Weinreb PH, Williams L, Maer M, Dunstan R, Salloway S, Chen T, Ling Y, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature. 2016;537(7618):50–6.

44. Conboy L, Varea E, Castro J, Sakouhi Ouertatani H, Calandra T, Lashuel HA, Sand C. Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors. Mol Psychiatry. 2011;16(5):533–47.